Opportunities in Indian Pharma Sector

This report, 'Opportunities in Indian Pharma Sector', provides extensive research and objective analysis on the Pharmaceutical sector in India. This report has been written to help clients in analyzing the opportunities critical to the growth of Pharmaceutical market in India. Detailed data and analysis will help the investors to comprehend the changing dynamics of the Pharmaceutical industry.

Key Findings

• India currently holds US$ six Billion of the $550 Billion global pharmaceutical industry; its share is increasing at 10% a year. As compared 7% annual growth for the overall world markets, this figure speaks of a very promising scenario
• Domestic pharmaceutical companies will increasingly be looking for consolidation across the value chain by forming partnerships or mergers with companies of complementary strengths. As drug discovery becomes more expensive, and the costs of administration and regulatory compliance continuously rise, these partnerships will become more central to Pharma companies' business proposition
• The Bio Pharmaceutical market is seeing a consistent growth trend since 2004, which saw record vaccine sales of US$ 386.3 Million and Marketing licenses being granted for over 25 recombinant therapeutic protein. The Diagnostics market size stands for US$138.2 Million

Key Issues and Facts Analyzed

The research report also addresses the issues and facts that are critical to your success:

• Emerging trends in the Pharmaceutical sector in India
• Key regulations and the policy environment in the industry
• Future prospects of the Pharmaceutical industry in India
• Key players in the Pharmaceutical market in India
• Opportunities and challenges in the Pharmaceutical market
• Effect of other factors prevailing in the economy on the Indian Pharmaceutical market

Key Players Analyzed

This section provides an overview of the key financial facts and figures vis--vis the prominent players in the Indian Pharmaceutical market like Cadila Healthcare Ltd, Cipla, Ranbaxy Ltd, Dr Reddy 's Laboratories Ltd, Nicholas Piramal India Ltd, Wockhardt Ltd, GlaxoSmithkline Pharmaceuticals Ltd and Pfizer Ltd.

Research Methodology Used

Information has been sourced from namely, books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, industry news and developments and through access to more than 3000 paid databases.

The analysis methods includes the following: Ratio Analysis, Historical Trend Analysis, Linear Regression Analysis using software tools, Judgmental Forecasting and Cause and Effect Analysis.

• 1. Analyst View2. Industry Overview
  • 2.1 World Overview of Pharmaceutical Industry
  • 2.2 India's Position in the Global Industry
• 3. Pharmaceutical Industry Performance
  • 3.1 Production of Bulk Drugs and Formulations
  • 3.2 Export and Import Trends in Pharmaceutical Industry
  • 3.3 Emerging Trends
    • 3.3.1 Contract Manufacturing
    • 3.3.2 Research & Development
    • 3.3.3 Clinical Trials
    • 3.3.4 Bio Pharmaceuticals
• 4. Analysis of Regulatory Frameworks and Policies Initiated in Industry Growth
  • 4.1 Indian Patent Law
  • 4.2 Drugs Price Control Order (DPCO)
  • 4.3 National Pharmaceutical Pricing Authority (NPPA)
• 5. Key Drivers of Pharmaceutical Industry
• 6. Opportunities and Threats
  • 6.1 Opportunities
  • 6.2 Threats
• 7. Mergers and Consolidations in Indian Pharmaceutical Sector
• 8. Recent News & Industry Developments
• 9. Key Players in Pharmaceuticals Industry
  • 9.1 Cadila Healthcare Ltd.
  • 9.2 Cipla Ltd.
  • 9.3 Ranbaxy Laboratories Ltd.
  • 9.4 Dr Reddy's Laboratories Ltd.
  • 9.5 Nicholas Piramal India Ltd.
  • 9.6 Wockhardt Ltd.
  • 9.7 GlaxoSmithkline Pharmaceuticals Ltd.
  • 9.8 Pfizer Ltd.
• List of Figures:
  • Figure 2-1: World - Pharmaceutical Market Revenue (in Billion US$), 2001-2005
  • Figure 2-2: World - Pharmaceutical Market Segment by Geographical Region (%), 2005
  • Figure 2-3: World - Pharmaceutical Market by Therapeutic Segmentation (%), 2004
  • Figure 2-4: India - Growth in the Pharmaceutical Industry Market (in Billion US$), 2005-2010F
  • Figure 3-1: India - Bulk Drugs and Formulations Export Trends (in Rs Crore), 1994-95 to 2003-04
  • Figure 3-2: India - Bulk Drugs, Formulations & Intermediate Import Trends (in Rs Crore), 1994-95 to 2004-05
  • Figure 3-3: World - Forecast for Contract Manufacturing and Research Services (in Billion US$), 2005-2009
  • Figure 3-4: India - R&D Investment in the Pharmaceuticals Industry (in Million US$), 1993-94 to 2000-01
  • Figure 3-5: India - R&D Expenditure by Company (in Million US$), 2004-05
  • Figure 3-6: India - Biotechnology Market Composition (%), 2004-05
  • Figure 5-1: India - Population (in Million), 2001-2005
  • Figure 5-2: India - Growth in Real GDP (%), 2000-2005
  • Figure 5-3: India - Real Personal Disposable Income (in Billion US$), 2000-2005
  • Figure 5-4: India - Per Capita Income (in Rs), 2002-2004
  • Figure 5-5: India - Urban Population (in Million), 2001-2005
  • Figure 5-6: India - Growth in Urban Population (%), 2001-2005
  • Figure 5-7: India - Number of Cardiac Disease Related Treatments (in Million), 2004-2008F
  • Figure 5-8: India - Rise in % of Population Aged 65 years and above (2000-2005)
  • Figure 6-1: India - Contract Research Market (in Billion US$), 2004-2008F
  • Figure 9-1: Cadila Healthcare Ltd. - Stock Performance
  • Figure 9-2: Cipla Ltd. - Stock Performance
  • Figure 9-3: Ranbaxy Laboratories Ltd. - Stock Performance
  • Figure 9-4: Dr. Reddy's Laboratories Ltd. - Stock Performance
  • Figure 9-5: Nicholas Piramal India Ltd. - Stock Performance
  • Figure 9-6: Wockhardt Ltd. - Stock Performance
  • Figure 9-7: GlaxoSmithkline Pharmaceuticals Ltd. - Stock Performance
  • Figure 9-8: Pfizer Ltd. - Stock Performance
• List of Tables:
  • Table 2-1: India - Pharmaceutical Industry, 2004
  • Table 2-2: India - Major Therapeutic Segments, 2004
  • Table 3-1: India - Bulk Drug & Formulations Production (1994-2004)
  • Table 3-2: India - Pharmaceuticals Market Export (in Rs Crore), 1994-95 to 2003-04
  • Table 3-3: India - Pharmaceuticals Market Imports (in Rs Crore), 1994-95 to 2004-05
  • Table 3-4: Contract Manufacturing Deals (in Million US$), 2004
  • Table 6-1: India - ANDA Filing by Mid-size Companies (FY 2004 to FY 2006)
  • Table 6-2: India - R&D Agreements with Foreign Partners
  • Table 9-1: Cadila Healthcare Ltd. - Ratio Analysis (2003-2005)
  • Table 9-2: Cadila Healthcare Ltd. - Financial Overview, 2005
  • Table 9-3: Cadila Healthcare Ltd. - Top Management
  • Table 9-4: Cipla Ltd. - Ratio Analysis (2003-2005)
  • Table 9-5: Cipla Ltd. - Financial Overview (in US$), 2004-2006
  • Table 9-6: Cipla Ltd. - Top Management
  • Table 9-7: Ranbaxy Laboratories Ltd. - Ratio Analysis (2002-2004)
  • Table 9-8: Ranbaxy Laboratories Ltd. - Financial Overview (in US$), 2003-2005
  • Table 9-9: Ranbaxy Laboratories Ltd. - Top Management
  • Table 9-10: Dr. Reddy's Laboratories Ltd. - Financial Overview (2003-2005)
  • Table 9-11: Dr. Reddy's Laboratories Ltd. - Top Management
  • Table 9-12: Nicholas Piramal India Ltd. - Ratio Analysis (2003-2005)
  • Table 9-13: Nicholas Piramal India Ltd. - Financial Overview (in US$), 2004-2006
  • Table 9-14: Nicholas Piramal India Ltd. - Top Management
  • Table 9-15: Wockhardt Ltd. - Ratio Analysis (2003 & 2004)
  • Table 9-16: Wockhardt Ltd. - Financial Overview (in US$), 2003-2005
  • Table 9-17: Wockhardt Ltd. - Top Management
  • Table 9-18: GlaxoSmithkline Pharmaceuticals Ltd. - Ratio Analysis (2002-2004)
  • Table 9-19: GlaxoSmithkline Pharmaceuticals Ltd. - Financial Overview (in US$), 2003-2005
  • Table 9-20: GlaxoSmithkline Pharmaceuticals Ltd. - Top Management
  • Table 9-21: Pfizer Ltd. - Key Financial Information (in Lakh Rs), 2004 & 2005
  • Table 9-22: Pfizer Ltd. - Top Management